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SINTESIS DAN PENILAIAN POLIMER DISULFIDA RANGKAI SILANG 
UNTUK PENYAMPAIAN DRUG KEPADA KOLON 
 
ABSTRAK 
 
Kolon telah dilaporkan sebagai tapak sasaran yang sesuai bagi penyerapan sistemik 
protein dan peptida terapeutik drug kerana aktiviti peptidase yang lebih rendah, 
meghampiri pH neutral dan keadaan ‘perbalahan’ yang kurang jika dibandingkan 
dengan kawasan lain daripada saluran pencernaan. Bentuk dosaj yang diformulasikan 
mesti melalui saluran pencernaan bahagian atas dalam bentuk utuh sebelum 
penghantaran drug kepada kolon. Penggunaan polimer disulfida sebagai satu 
penghantaran responsif bakteria merupakan salah satu strategi untuk menyasarkan 
drug kepada kolon bagi melepaskan drug secara khusus dalam kolon. Oleh itu, 
objektif kajian ini adalah untuk mensintesis satu polimer disulfida berangkai silang 
yang baru  berasaskan asid amino sisteina untuk sistem penghantaran drug kepada 
kolon dan menilai polimer-polimer ini di bawah keadaan keupayaan redoks yang 
rendah. Kajian dimulakan dengan sintesis polimer disulfida rantai bercabang 
berasaskan asid amino sisteina. Sisteina terlindung bertindak balas dengan boron 
trifluorida dietil etherat dalam tindak balas perangkaian dengan dua nilai setaraan 
asid (trifenilmetil) thiopropanoik untuk menghasilkan satu monomer yang 
mengandungi satu kumpulan thiol terlindung pada setiap tiga rantai bercabang. 
Proses penyahlindungan dijalankan dengan menggunakan asid trifluoroasetik dan 
trietilsilana untuk menghasilkan monomer trithiol. Monomer trithiol ini kemudiannya 
mengalami pempolimeran melalui pengoksidaan udara dengan 1,2-ethanadithiol 
mengikut gabungan nisbah tertentu untuk menghasilkan empat jenis polimer, iaitu 
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P10, P11, P151 dan P15. Semua sebatian yang disintesiskan telah dikenalpasti 
dengan NMR, IR, LC-MS, analisis CHNS, spektroskopi Raman, SEM-EDX dan peta 
elemental. Polimer-polimer yang telah disintesiskan dinilai dengan ujian penurunan 
kimia dengan menggunakan larutan zink/asid asetik. Kesesuaian polimer ini sebagai 
sasaran penghantaran drug kepada kolon telah diuji secara in vitro menggunakan 
kaedah keadaan simulasi dalam kolon. Bacteroides fragilis telah digunakan dan 
kepekatan thiol diukur dengan reagen Ellman. Tempoh masa inkubasi dijalankan 
pada masa 5, 30 dan 180 jam. Keputusan daripada spektroskopi Raman menunjukkan 
ketiadaan puncak –SH dan kehadiran puncak S-S membuktikan bahawa polimer 
disulfida telah disintesiskan. Ujian penurunan kimia menunjukkan semua polimer 
telah mengalami penurunan selepas 0.5-1.0 jam tetapi kepekatan thiolnya dikesan 
pada kadar berlainan bagi polimer-polimer berlainan. Keputusan SEM-EDX 
menunjukkan morfologi permukaan yang berlainan bagi polimer-polimer yang telah 
disintesiskan. Peta elemental menunjukkan penyerakan elemen-elemen yang sekata 
dalam polimer-polimer tersebut. Dalam ujian degradasi bakteria, polimer-polimer ini 
telah dibiodegradasikan di dalam medium bakteria kolon secara anaerobik. 
Degradasi rangkaian polimer “longgar” adalah lebih berkesan dengan penurunan 
polimer P15 (1.0 mol monomer trithiol : 5.0 mol monomer dithiol) menunjukkan 
bacaan tertinggi (118.6 x 10-6 M pada masa 180 jam) jika dibandingkan dengan 
polimer-polimer lain daripada ujian Ellman bagi thiol. Keputusan ini berhubungkait 
dengan persetujuan umum bahawa biodegradabiliti bergantung kepada 
kebolehkembangan polimer-polimer ini dalam keadaan akues. Kesimpulannya, 
polimer disulfida berangkai silang telah berjaya dikembangkan di mana ia 
mempunyai aplikasi untuk penghantaran drug kepada kolon secara selektif. 
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SYNTHESIS AND EVALUATION OF CROSS-LINKED DISULPHIDE 
CONTAINING POLYMERS FOR COLONIC DRUG DELIVERY 
 
ABSTRACT 
 
Colon has been reported as a favourable target site for the systemic absorption of 
therapeutic protein and peptide drugs, because of its lower peptidase activity, near 
neutral pH and less hostile conditions as compared with other regions of 
gastrointestinal tract. The formulated dosage form must pass through the upper 
gastrointestinal tract in intact form before delivering the drug to the colon. The use of 
disulphide polymers, a bacteria responsive delivery, is one of the strategies for 
targeting drugs to the colon and to release drug specifically in the colon. Therefore, 
the objective of this study was to synthesise a new cross-linked disulphide containing 
polymer based on amino acid cysteine for colon drug delivery system and to evaluate 
the polymers under the condition of a low redox potential. The work was initiated 
with the synthesis of a branch-chained disulphide polymer based on the amino acid 
cysteine. The protected cysteine was reacted with boron trifluoride diethyl etherate in 
a coupling reaction with two equivalents of (triphenylmethyl) thiopropanoic acid, 
giving rise to a monomer that contained a protected thiol group on each of its 3 
branching chains. The deprotection process was conducted using trifluoroacetic acid 
and triethylsilane which afforded the trithiol monomer. The trithiol monomers were 
polymerised by air-oxidation with 1,2-ethanedithiol using various ratio combinations 
to yield four types of polymers mainly, P10, P11, P151 and P15. All compounds 
synthesised were characterised by NMR, IR, LC-MS, CHNS analysis, Raman 
spectrometry, SEM-EDX and elemental mapping. The synthesised polymers were 
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evaluated in chemical reduction studies which were performed in zinc/acetic acid 
solution. The suitability of the polymer to be used in a colon-targeted drug delivery 
was investigated in vitro using simulated conditions of the colon. Bacteroides fragilis 
was used and the thiol concentrations were detected by Ellman’s reagent. Incubation 
periods were 5, 30 and 180 hours. The Raman spectroscopy results showed the 
absence of –SH peak and the presence of S-S peak, indicating that the disulphide 
polymers were synthesised. Chemical reduction studies showed that all polymers 
were reduced after 0.5-1.0 hour but detected at different thiol concentrations for 
different polymers. SEM-EDX results showed different surface morphologies of the 
polymers synthesised. Elemental mapping exhibited homogeneous distribution of the 
elements in the polymers. In the bacterial degradation studies, the polymers were 
shown to be biodegraded in the anaerobic colonic bacterial medium. Degradation 
was more pronounced in polymers with “looser” polymeric networks, with the 
reduction of polymer P15 (1.0 mol trithiol monomer : 5.0 mol dithiol monomer) 
indicated the highest reading (118.6 x 10-6 M at 180 hours) when compared with 
other polymers from the Ellman’s test for thiol. This result complements the general 
consensus that biodegradability relies on the swellability of polymers in an aqueous 
environment. In summary, a cross-linked disulphide containing polymer for colonic 
drug delivery has been successfully developed, which has application for selective 
delivery of drugs to the colon. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Background  
Oral drug delivery is the most traditional and widely accepted route of drug 
administration (Ritschel, 1991; Mrsny, 1992; Lai et al., 2008) due to its convenience 
and patient-friendly route of drug administration. Orally administered drugs are 
usually intended for rapid dissolution in the upper gastrointestinal (GI) tract, where 
many drugs are most effectively absorbed. However, for local treatment of 
conditions of the lower GI tract or delivery of biotechnology products such as 
proteins and peptides, this approach is inadequate, costly and associated with 
undesirable adverse effect. Hence, the idea of specifically targeting drugs to the 
colon itself has stimulated great interest, with much work already carried out in this 
area of drug delivery (Ritschel, 1991; Mrsny, 1992; Siccardi et al., 2005; Lai et al., 
2008). The recognition of the importance of this region of the GI tract, not only for 
local but also for systemic therapy could be the main reason (Tozer et al., 1995). 
 
At present, the specific drug delivery to the colon has secured prominence primarily 
(Ibekwe et al., 2006) because of the therapeutic benefits to be gained from topical 
treatment of local disorders such as irritable bowel disease, ulcerative colitis, 
carcinomas, inflammatory bowel disease, Crohn’s disease and infection (Yeh et al., 
1995; Schact et al., 1996; DiPirio and Bowden, 1997; Gupta et al., 2001). The colon 
is evaluated as a more favourable target site for the systemic absorption of 
therapeutic protein and peptide drugs (Ashford and Fell, 1994) because of its lower 
peptidase activity, a near neutral pH, less hostile conditions as well as an increased 
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responsiveness to absorption enhancers that would otherwise be inactivated in the 
upper gastrointestinal regions (Rubinstein, 1995; Van den Mooter and Kinget, 1995; 
Watts and Illum, 1997).  
 
1.2 Colonic anatomy, physiology and its microbial distribution 
1.2.1 Anatomy of the gastrointestinal tract 
The gastrointestinal digestive tract, which is also known as the alimentary canal is a 
system of organs within multicellular animals that take in food, digest to extract 
energy and nutrients, and expels the resulting waste (Figure 1.1). The normal human 
adult male GI tract consists of the upper and lower GI tracts and is approximately 6.5 
meters long (Anthea et al., 1993).  
 
The colon, or large intestine, forms the lower part of the GI tract and extends from 
the ileocecal junction (shared with the small intestine) to the rectum and finally anus 
as shown in Figure 1.2. The colon is composed of the caecum (with its associated 
vermiform appendix), three relatively straight segments; the ascending segment, 
transverse segment and descending segment, and sigmoid region. Sigmoid colon is 
the terminal portion of the colon and is S-shaped, which empties into the rectum, the 
last part of the intestinal tract. The colon is approximately 1.5 m in length in the adult 
human and has an average diameter of about 6.5 cm. However, the diameter varies 
from approximately 9 cm in the caecum to approximately 2 cm in the sigmoid colon 
(Mrsny, 1992). Unlike the small intestine, the colon does not have villi although it 
does demonstrate crescentric folds, which modestly increase the internal surface area 
of the colon to roughly 1300 cm2 (Cummings and MacFarlane, 1991). Although 
rodents and guinea pigs are commonly used as models to study colonic drug 
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delivery, the anatomy in these two animals are different (compared to humans) with 
shorter colon in guinea pig and slightly longer in rats (Pettersson et al., 1976). 
Guinea pig has a large caecum, about three times the size of its stomach (Friend, 
1991) and rodent has a different mucosa-associated flora from human (Bitton and 
Marshall, 1980). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 : Upper and lower gastrointestinal tract (after Friend, 1991). 
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Figure 1.2 : (i) Structure of the large intestine (after Friend, 1991) and                 
                   (ii) layers of the colon that make up the bowel wall. 
 
 
 
The surface area of the colon is low if compared to the small intestine which plays a 
role to digest foods and absorb nutrients. The presence of villi and microvilli, as a 
result of crescentric folds, makes absorption more efficient (Steed et al., 1989). The 
colon is involved in the fermentation of polysaccharides and proteins, consolidation 
of the intestinal contents into faeces by the absorption of water and electrolytes and 
the formation, storage and elimination of faecal material (Edwards, 1997). The distal 
colonic contents becoming more viscous as a result of rapid water absorption in the 
ascending colon which estimated that the human colon contains only 220g of wet 
contents which is equivalent to just 35 g of dry matter (Cummings et al., 1990). The 
circulation of chyme across the colonic mucosa by segmenting movements helps the 
absorption of fluid and salt. As potassium and bicarbonate ions are secreted, sodium 
and chloride ions are absorbed in the healthy human colon (Binder and Sandle, 
1994).  
(i) 
(ii) 
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1.2.2 Microbial and gastrointestinal system 
The number of microbial are restricted in the human stomach due to the pH of the 
stomach contents (as low as pH 2) and the relatively swift flow (transit time of 4-6 
hours) of the digestion through the stomach and small bowel (Gibson and 
Macfarlene, 1995). Lactobacilli and streptococci are the principal microbial types 
encountered in the stomach and upper small bowel (Lee, 1985). Unlike the majority 
of microbes entering the GI tract through indigested food, lactobacilli and 
streptococci are acid-tolerant bacteria and can survive passage through the stomach. 
The lactobacilli and streptococci which are carried into the GI tract from the oral 
cavity and pharynx by saliva are considered to be merely passing through the upper 
GI tract and they are described as transients (Tannock, 1995). There has been a view 
considering that the healthy human stomach is never to be colonised by microbes 
(Lee et al., 1993).  However, this view has been altered by the long-term association 
of a spiral-shaped motile bacterium called Helicobacter pylori with the mucosal 
surface of the stomach antrum. These bacteria are considered as pathogens rather 
than normal microflora because of their involvement in the causation of 
inflammation of the stomach (chronic active gastritis) and in the formation of peptic 
ulcers (gastric or duodenal ulcers). Figure 1.3 shows the distribution of selected 
bacteria in the GI tract.    
 
The ileum, as the last third of the small bowel, harbours a large number of microbes 
than are found in the upper regions of the GI tract. The large bowel consists of at 
least 400 to 500 different species of bacteria, as well as yeast, fungi and protozoa and 
is considered the most densely colonised region of the digestive tract of humans. The 
large number of bacteria (Table 1.1) includes a very complex population of aerobes, 
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facultative anaerobes and strictly anaerobic species with the non sporing anaerobes 
predominating. There are four microhabitats identified in the colon, namely, the 
surface of the epithelial cells, the mucus gel overlying the villi, the mucus gel within 
crypts and luminal contents and the role of each microhabitat varies significantly 
(Freter, 1983).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 : Distribution of selected bacteria in the GI tract (after Basit, 2005). 
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Table 1.1 : The 25 most prevalent bacterial species in the faeces of human subjects 
consuming a Western diet (109-10 bacteria per gram wet weight). 
 
1. Bacteroides vulgatus 14. Peptostreptococcus productus 
2. Bacteroides species, other 15. Eubacterium lentum 
3. Bacteroides fragilis 16. Facultative streptococci, other 
4. Bacteroides thetaiotaomicron 17. Fusobacterium russii 
5. Peptostreptococus micros 18. Bifidobacterium adolescentis A 
6. Bacillus species (all) 19. Bifidobacterium adolescentis C 
7. Bifidobacterium adolescentis D 20. Bacteroides clostridiiformis ss. 
clostridiiformis 
8. Eubacterium aerofaciens 21. Peptostreptococcus prevotii 
9. Bifidobacterium infantis, other 22. Bifidobacterium infantis ss . liberorum 
10. Ruminococcus albus 23. Clostridium indolis 
11. Bacteroides distasonis 24. Enterococcus faecium 
12. Peptostreptococcus intermedius 25. Bifidobactrium longum ss. longum 
13. Peptostreptococcus sp. 2  
 
 
 
1.2.3 Factors affecting gastrointestinal microflora 
There is a natural resistance to the alteration of the flora by introduction of bacteria 
even if they are of species commonly encountered in the intestine. The changing of 
this resistance is understandable; the bacteria that comprise the flora have adapted to 
life in the intestine whereas freshly introduced strains require time to adapt. The 
important role in preventing the flora overrunning the host and determining the 
distribution of the flora within the intestine must be played by the intestinal 
physiology and host defence mechanisms. There are some bacteria which are 
considered beneficial (bifidobacteria and lactobacilli) while others are benign 
(saccharolytic species of clostridia and bacteroides) and are thought to suppress the 
overgrowth of those that are harmful to human health (clostridium species and 
enterobacteriaceae) (Kolida et al., 2000).   
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Alteration in the composition or the metabolic activity of intestinal microflora can 
also be linked to diet. The nature of the meal affects gastric emptying and therefore 
indirectly affects the distribution of bacteria. Nevertheless, some studies of the effect 
of diet on the composition of the flora in human suggested that diet has little effect 
on the composition of intestinal flora (Moore and Holderman, 1975; Mitsuoka, 
1978). Studies on people living on different diets in various countries under different 
environmental circumstances have shown some differences in the relative numbers 
of some of the groups of bacteria present in their faeces. The few attempts to change 
the composition of the flora by controlled changes in diet have, in general, been 
unsuccessful (Drasar et al., 1976; Cummings et al., 1978; Drasar, 1981). Suggestions 
have been made on the observations that colonic bacteria obtain most nutrients from 
gut secretions and shed mucosal cells rather than from unabsorbed residues in the GI 
tract. Furthermore, it is difficult to demonstrate the changes in bacteria species while 
changes in the bacterial metabolic activities occur (Simon and Gorbach, 1987). Table 
1.2 shows the factors influencing the gut microflora. 
 
Microbial flora in the gut can be influenced by certain diseases or treatment with 
antibiotics (Friend and Tozer, 1992). Bacterial growth in the stomach may increase if 
the hydrochloric acid secretion is decreased caused by certain diseases (Rowland, 
1988). The microbial colonisations affected by host factors are related to the flow of 
contents, oxygen tension and pH. Microbial multiplication cannot usually overcome 
the rate during peristalsis at the top of the small intestine where flow rate is the 
greatest (Drasar and Barrow, 1985). Peristalsis slows down to almost motionless 
upon reaching the distal ileum and when approaching ileo-caecal valve and the rise 
in bacterial population within this region can be seen. Gross changes of some 
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microorganisms in the environment within the gut can occur when antibiotic 
treatments are given where it suppresses the bacterial growth (Goldin and Grobach, 
1977).  
 
Table 1.2 : Factors influencing the gut microflora (after Rowland, 1988).  
Host factors i)   Individual difference in strain and species: 
     Acid or alkali secretion 
     Intestinal motility 
     Intestinal structure 
     Levels of endogenous nutrients 
     Redox potential 
     Bile salts 
     Antibodies 
 
ii)  Age 
 
iii) Gastrointestinal disorders 
 
Environmental factors i)   Drugs 
ii)  Diet 
iii) Xenobiotics 
Bacterial factor i)   Bacterial metabolites  
ii)  Bacterial interactions 
iii) pH 
              
 
1.2.4 Metabolic activities-role of microflora 
The massive microflora in the colon fulfills its energy needs by fermenting the 
various types of substrates that have been left undigested in the small intestine. 
Glucose is considered one of the substrates that can be easily utilised by the 
microorganisms and barely reaches the colon since glucose and other easily 
digestible substrates are well absorbed or utilised in the upper GI tract. The 
physiological roughage (McBee, 1970) including di, tri-polysaccharides, and 
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mucopolysaccharides (Rubinstein, 1990) are the indigestible portion of the food that 
reach the colon. Bacteria produce a wide range of reductive and hydrolytic enzymes 
to utilise this roughage as a source of carbon such as β-xylosidase, β-glucuronidase, 
β-galactosidase, α-arabinosidase, azoreductase, nitroreductase, urea hyroxylase and 
deaminase (Scheline, 1973; Kinget et al., 1998). 
 
Anaerobic bacteria of the colon have been found to be able to react to the constantly 
changing mixture of complex carbohydrates entering the colon by recognising a 
variety of substrates and producing the appropriate digestive enzyme (Salyers et al., 
1978). Due to this, various systems have been developed for drug delivery to this 
part of the GI tract such as prodrugs (Sinha and Kumria, 2001a) and systems based 
upon biodegradable polymers which are specifically degraded by digestive enzymes 
(Van den Mooter et al., 1995; Sinha and Kumria, 2001b). 
 
The presence of the vast microflora in the colon results in changes in redox potential. 
The redox potential which are considered as an expression of total metabolic and 
bacterial activity has been found to be -67+ 90 in the proximal small bowel; -196+ 97 
in the distal small bowel and -415+72 in the right colon (Stirrup et al., 1990; Wilding 
et al., 1994). According to Grim and Kopecek (1991), redox mediators such as 
benzyl viologen and flavin mononucleotide, act as shuttles between the intracellular 
enzymes and the extracellular substrates. One of the highly specific mechanisms 
used for targeting drugs to the large bowel is the microflora-induced changes in the 
redox potential which causes reduction of bonds like the azo bonds and disulphide 
bonds. Therefore, numerous drugs are being linked to such carrier moieties with 
these bonds where these linkages are increasingly being exploited for drug delivery 
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to this part of the GI tract. In addition, various drug-carriers for colon specific drug 
delivery have been designed which either utilise the presence of enzymes or the 
redox potential of this particular part of the GI tract for drug targeting (Sinha and 
Kumria, 2003).  
 
1.3 Colonic drug targeting 
The concept of drug targeting to the desired site of drug action is not new. The 
interest in the treatment of colonic disorders and the delivery of peptide drugs to the 
colon has become more attractive to researchers. Colon-specific drug delivery has 
met the challenge of drug delivery to the small intestine as it can be easily achieved 
by using enteric coating polymers that are soluble in the neutral environment of the 
small intestine. The formulated dosage form for colon-specific drug delivery must 
pass through the upper GI tract in intact form before delivering the drug to the colon. 
After all, numerous investigations have shown that some inflammatory (Wilson and 
Washington, 1989) and antidiabetic (Gleiter et al., 1985) drugs are better absorbed 
from the colon rather than the small intestine. 
 
1.3.1 Colonic absorption 
The colon plays an important role in the reabsorption of water and the elimination of 
undigested material includes cellulose, desquamated epithelial cells, unabsorbed 
remains of intestinal secretions and bacteria (Philips, 1984). The dehydration of 
faecal material happens when a variety of active and passive transport processes are 
involved in the events of massive water resorption. In the outlook of this case, human 
colon receives approximately 1L of chyme from the small intestine, while about 150 
ml of faeces are eliminated per day (Rangachari, 1990).  
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The lubricating actions of mucus secreted by the colonic mucosa assist the 
elimination of undigested material such as faeces. Colonic mucus consists of rather 
large (up to 2 x 106 Da), carbohydrate-rich (approximately 80% dry weight) and 
negatively charged glycoproteins (Allen, 1982). The mucus becomes hydrated to 
form a gel with unique chemical and physical properties resulting from the secretion 
of colonic goblet cells. The remarkable properties of this mucus are the ability to 
bind macromolecules, coat bacteria, cushion particulate matter and most importantly 
to protect the colonic mucosa from the dehydrated luminal contents when moving 
towards the rectum. The mucus layer is highly charged with a sieve-like nature, due 
to this, it can affect the transit of large, negatively-charged drug molecules. Such 
drug-mucus repulsion could prevent the drug from approaching the epithelial surface 
hence impeding drug absorption. In contrast, drug binding to mucus might facilitate 
even longer residence time, thereby possibly increasing drug absorption. However, 
the enhanced effects of enzymes and environmental degradation which might 
accompany the long residence time must not be ignored (Le, 1998). 
 
The transport pathways of the colon provide for rapid and specific active bi-
directional transport of ions across the epithelial layer. The colon has no active 
transporters for organic nutrients in the mature organ and hence, no chance for drug 
molecules to be absorbed back in transport compared to the small intestine. In the 
small intestine, examples of this kind of active absorption of drugs are seen for 5-
fluorouracil (Bronk and Hastewell, 1987; Bronk et al., 1987) on the pyrimidine 
transporter and antibiotics on the peptide transporters (Iseki et al., 1989; Sinko and 
Amidon, 1989; Dantzig and Bergin, 1990). The drug absorption in the colon is 
limited due to the lack of such transporters and hence, limits the scope for drug 
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design with respect to mediated transport across the epithelial barrier. The potential 
for drug design with respect to carrier mediated transport across the colon may be 
restricted due to the apparent lack of organic nutrient transporters. However, the 
active transport pathways of the colon have been reviewed (Hastewell et al., 1991) 
and reported that the transmucosal and membrane potential differences may be of 
significance in the absorption of ionised or ionisable drugs (Hogben et al., 1958; 
Schanker et al., 1958). The absorption of the drug will be improved as the bulk water 
absorption in this region of the intestine will provide scope for solvent drag.  
 
The passive and active transport processes in the colon may indirectly enhance the 
uptake of water soluble drug molecules. These processes occur with the net secretion 
of potassium and bicarbonate and the net absorption of sodium and chloride, 
resulting in dehydration of colonic contents (Guyton, 1986). Consequently, the drift 
of water can act as a driving force for the uptake of water-soluble drug molecules. 
Residual fatty acids are absorbed by the colon after assimilation of lipids in the small 
intestine which will provide a similar driving force scenario and hence, furnish 
another route for drug absorption. The paracellular (the most promising means of 
general drug delivery in the colon) transport to water and small cation is limited due 
to the occluding tight junctions at the locating neck of colonic cells (Rangachari, 
1990; Nellans, 1991). Thus, transcellular ionic gradients is driving the movements of 
ions and water and giving a ‘leaky’ condition at the proximal colon than the distal 
colon (Luciano et al., 1984). In order to maximise local delivery as well as enhance 
absorption, it is desirable that drugs delivered to the colon are maintained in the 
proximal colon (Wills et al., 1984).  
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Drugs that are absorbed in the small intestine across the submucosa into venous 
capillaries are transported to the liver via the hepatic portal vein. In the liver, 
significant first-pass metabolism occurs which therefore retards the amount of drugs 
reaching the systemic circulation to exert their effects. In the colon, drugs absorbed 
can be taken up by venous and/or lymphatic capillary beds. The venous drainage of 
colon will go into the hepatic-portal circulation after passing through the superior 
and inferior mesenteric veins and there is no direct systemic venous drainage from 
any region of the colon (Muranishi, 1989). On the other hand, uptake of drug 
molecules into the lymphatic system allows direct entry into the systemic circulation 
bypass immediate transport to the liver which results in less metabolic degradation of 
the absorbed drugs. This phenomenon indirectly gives one potential advantage of 
delivering drugs in their intact form to a site of absorption in the colon. The 
suggestion of increasing drug uptake can occur by increasing lymphatic uptake 
(Schuette and Rose, 1986) are proven by the increment in the colonic absorption of 
1,2-dimethylhydrazine following high levels of dietary fats (Kvietys et al., 1981). 
Thus, peptide absorption may be feasible since lymphatic uptake of large sized 
molecules may occur.  
 
One of the targets is to use the colon as a site for oral absorption of therapeutic 
peptides and proteins as they can be absorbed intact from the GI tract (Smith et al., 
1992; Garnder, 1994). The bioavailability of therapeutics peptides and proteins 
administered through colon is extremely low because the colonic epithelium is 
poorly permeable and does not allow sufficient transport of most drugs, particularly 
proteins and peptides (Woodley, 1994). There has been limited success in increasing 
the amount of drug absorbed, which has been achieved by using absorption 
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enhancers and protease inhibitors to assess their effectiveness in promoting colonic 
permeability (O’Hagen et al., 1987). Some prominent examples are β-lactam 
antibiotics (Mrestani et al., 2006), calcitonin (Kamei et al., 2009), cyclosporin (Zhou 
et al., 2009), renin inhibitors (Staessen, 2006), somatostatin octapeptide analogue 
(Prieto et al., 1999), octreotide (Cervin et al., 2009), salicylates, water-oil-water 
emulsions, surfactants, bile salts, combinative promotion effects of azone and 
fusogenic fatty acids and lipids (Mackay et al., 1997). Protection of the peptide from 
the digestive functions of the stomach and small intestine must be ensured in the 
mode of delivery or even circumvent the harsh condition entirely by accessing the 
large intestine via the rectum.  
 
1.3.1.1 Barriers to colonic absorption 
The rapid and nonselective uptake of molecules from the colonic lumen is limited by 
various hypothetical physical and enzymatic barriers (Figure 1.4). Enzymatic or 
environmental degradation of the drug can occur in the lumen of the colon by 
resistant bacteria or released bacterial products. Selective or nonselective drug 
binding by the renewal and continuously flowing barrier produced by goblet cell 
exocytosis will give a difficult physical barrier to drug uptake. Examples of drugs 
that can bind to mucus are penicillins, cephalosporins and aminoglycosides (Nubuchi 
et al., 1986). The release of mucus from goblet cells is stimulated by particular drugs 
which may hinder their absorption. Furthermore, the diffusion of large delivery 
structures or molecules might face difficulty if they pose a similar charge as the 
negatively charged mucin glycoprotein matrix. Although the uptake of drugs could 
be stimulated by modification of this layer using mucolytic agents, the function of 
normal colon requires an intact mucus layer (Mack and Sherman, 1991) which will 
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implicate a diversity of disease processes and pathological conditions (Chadee et al., 
1991). The absorption of lipophilic drugs will also be affected by the unstirred water 
layer between the mucus layer and the epithelial cell surface (Rahman et al., 1986).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 : Barriers to the colonic absorption of drugs (after Mrsny, 1992). 
 
 
The level of the epithelia is observed as the most problematic site of drug delivery in 
the colon. There are enzymatic activities related with colonocytes and are mostly 
associated with the proximal vs. distal colon (Brasitus and Dudeja, 1985). The 
transepithelial movement is limited by the intercellular junction tight complex 
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(occluding junctions) of essentially biomolecules that avoid enzymatic destruction. 
There are two possible routes that drugs are successfully transported across the 
epithelia, namely, transcellular and paracellular. Most drugs are successfully 
delivered in the colon by the passive transcellular process. Small and amphipathic 
drugs will readily diffuse across colonic epithelial cells by a series of partitions 
between membrane lipid and the aqueous environments. Nevertheless, the drug 
needs to be stable to the environments it encounters on its transit through the colonic 
epithelial cell upon successful passive transcellular. Passive drug absorption in the 
proximal colon will be increased by the membrane lipid fluidity of proximal 
colonocytes which is greater than distal colonocytes (Brasitus and Dudeja, 1985). 
Nonetheless, thermodynamic barriers of passive diffusion between lipid membranes 
and aqueous compartments can become too large to overcome (Cooper and Kasting, 
1987) and diffusional model breaks down as drug size and hydrophilicity or 
hydrophobicity increases (Jackson, 1987).  
 
Unlike passive transport, pathways for active transcellular transport of large drug 
molecules are highly planned out. The uptake of drugs at the luminal surface was 
initiated at carrier-mediated uptake, pinocytotic endocytosis or receptor-mediated 
endocytosis. In order to gain a successful transcellular transport of a molecule 
entering the ephithelial cell via a carrier-mediated transporter event, the compound 
must be stable in the cyctoplasm. Furthermore, it must also be capable of migrating 
to the basolateral membrane and then must find some means of traversing this 
membrane to gain access to the submucosal space (Mrsny, 1992). The endocytotic 
event will follow a constitutive pathway where it fuses with a lysosome (Mellman et 
al., 1986; 1987). Although in the work carried out by Kopecek (1990) using prodrugs 
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that become activated upon reaching the hostile environment of the lysosomal 
compartment was unclear. Leupold et al. (2009) has developed an apolipoprotein E-
derived peptide, A2 that efficiently translocates across cell membranes which is 
mediated by endocytotic processes. 
 
1.3.2 Absorption of drugs from the colon 
1.3.2.1 Conventional drugs 
With a number of exceptions, the majority of drugs are absorbed from the GI tract by 
passive diffusion. Small intestine will tend to absorb the di- and tripeptides which are 
generated from protein digestion. This means that certain drugs contain chemical 
structures, which allow them to be carried across the small intestine wall by the di- 
and tripeptide active transport mechanisms, for example, angiotensin converting 
enzyme (ACE) inhibitors and β-lactam antibiotics (Smith et al., 1992). There will be 
possibility of some drugs with high lipophilicity epithelial cells being absorbed into 
the systemic circulation via the lymphatic system (Wilson et al., 1989).  
 
Drugs can be absorbed passively by two routes, i.e. paracellular or transcellular 
(Figure 1.5). The transport of drug molecules through the tight junctions between 
cells and most applicable for the hydrophilic drugs is called paracellular absorption, 
while transcellular absorption involves the passage of drugs through cells and is the 
route for most lipophilic drugs. According to studies in rat performed by Taylor et al. 
(1989), paracellular absorption was found to be constant throughout the small and 
large intestine, but transcellular absorption appears only to the small intestine. 
Although the absorption of paracellular of many drugs in the colon is poor due to the 
tight epithelial cell junctions (Powell, 1981) and lower surface area, the colon can be 
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a more selective site for absorption compared to the small intestine. Some examples 
of drugs shown to be well absorbed are ibuprofen (Moustafine et al., 2006), 
theophylline, glibenclamide (Brockmeier et al., 1985), diclofenac (Ambrogi et al., 
2008), oxprenolol (Verhoeven et al., 1989) and metoprolol (Dahan et al., 2009). 
However, there are a number of drugs which are not absorbed by the colon including 
lithium, cimetidine, buflomedil (Wilson et al., 1991), piretanide (Brockmeier et al., 
1986), furosemide (Bieck, 1989) and chlorothiazide (Riley et al., 1992).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 : Illustration of the main pathways of intestinal drug absorption: (1) 
Transcellular absorption; (2) paracellular absorption; (3) transcellular absorption 
followed by incorporation into chylomicron and transport into lymphatic system; (4) 
Active transport  
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Many sustained-release dosage forms rely on a degree of colonic absorption to 
remain therapeutically effective (Wilson et al., 1989). In a study using an osmotic 
tablet formulation containing oxprenolol, the drug availability was higher in subjects 
where tablets resided longer in the colon (Bieck et al., 1989). Thereupon, drug 
therapy could be compromised by using a once-a-day sustained-release formulation 
in cases of abnormality rapid GI transit. As insufficient colonic absorption has 
prevented and will continue to impede the development of sustained-release dosage 
forms for many drugs, therefore adequate knowledge of colonic absorption is 
important when developing related formulations.  
 
1.3.2.2 Metabolically labile drugs 
Peptide and protein drugs are expected an ever-increasing interest as novel and 
effective class of therapeutic agents (Cohen and Bernstein, 1996). However, their use 
is limited by the rapid clearance from body compartments, which can lead to the 
administration of exceptionally high doses to maintain an acceptable therapeutic 
level which may cause toxic effects. Therefore, the realisation of smart systems that 
allow site-specific administration of protein drugs has led to intense investigation. 
There are some specific sites of action such as organs, tissues, cells and molecular 
targets that protein and peptides have also been delivered (Hirabayashi et al., 1996). 
In consideration of targeting a specific site of action, it depends on the aid of a 
delivery vehicle that relies on specific properties of the protein or peptide to be 
delivered and the unique properties of tissues being targeted.   
 
The oral absorption of peptide and protein drugs is mostly limited by degradation in 
the acidic environment of the stomach, low mucosal permeability, extensive first 
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pass metabolism by the absorbing membrane and liver, enzymatic degradation in the 
small and large intestine and rapid small intestinal transit (Watts and Illum, 1997). In 
comparison to the stomach and small intestine, colon relatively lacks degradative 
enzymes and which is one of the most attractive properties of the colon as a site for 
peptide and protein delivery. A group of enzymes called peptidase that tend to break 
down peptides is found in highest concentrations in the intestine and lowest in the 
colon. As discussed earlier, the role of microflora is important as there is significant 
protease and peptidase enzymes activity in the colon. Therefore, poor stability of 
peptide and protein drugs can result within the colon and the opportunities for 
absorption are still relatively limited, although better than in the small intestine 
(Rama Prasad et al., 1996).  
 
There has been reported work on human calcitonin where the peptide was directly 
instilled into the distal colon using a colonoscope following administration of an 
enema to clear faecal matter (Antonin et al., 1992). The therapeutic dose for 
calcitonin is delivered once a day. This greatly simplifies the dosing requirements 
and is becoming a particularly attractive peptide for GI tract delivery. The direct 
administration of human calcitonin into a colonic loop in anaesthetised rats to 
examine the bioavailability was performed (Hastewell et al., 1992). This was 
compared to the pharmacodynamic effect, detectable in normal juvenile animals, of a 
reduction in plasma calcium levels in response to human calcitonin. This study was 
related to administering of human calcitonin in the transverse colon of patients 
(Antonin et al., 1996) where the mean bioavailability was higher than found to be in 
a previous study (Antonin et al., 1992). It was concluded that the transverse colon 
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was a better absorption site for human calcitonin than the distal colon although there 
are differences in the luminal environment between patients and healthy subjects.  
 
Further studies have been conducted in human to test hypotheses concerning the 
optimisation of colonic delivery of peptides (Hastewell et al., 1995). Although the 
colon has been shown to be lower in peptidase activity than the proximal GI tract, the 
traces of pancreatic enzymes were retained by the colon. Results proved that low 
concentrations of human calcitonin are rapidly degraded by human faecal material 
(Hastewell et al., 1995). There was a dose dependent effect on the time taken for 
50% degradation at 37°C and varied in the presence of 16 000 units of aprotinin, a 
protease inhibitor. In the presence of aprotinin, the bioavailability showed a decrease 
leading to the difficulty in explanation. The author suggested that aprotinin may have 
caused precipitation of the dose from solution within the colonic lumen. It is 
concluded that care must be taken in co-administration of compounds which may 
affect the intraluminal physiochemical environment of the dose although metabolism 
within the colonic lumen may restrict absorption of intact peptide. In another study, 
the bioavailability of salmon calcitonin showed a 7.1-fold increase by administration 
in the presence of taurodeoxycholate (TDC) and was further increased in the form of 
TDC proliposomes (Song et al., 2005). This indicated that the validity of the 
hypothesis that the local delivery of a drug to the site of absorption may be 
favourable for its efficient absorption in the colon.      
 
Colonic peptide delivery gives some advantages such as longer residence time, low 
metabolic activity, colonic bacterial enzymes present may offer targeting 
opportunities, responsive to absorption enhancers, the bulk water absorption in this 
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region of the intestine may provide scope for solvent drag and the transmucosal and 
membrane potential differences may be of significance in the absorption of ionised 
or ionisable drugs. However, despite the colon’s apparent attractiveness as a route for 
the oral delivery of peptides, only very limited bioavailability can be demonstrated 
for this route in vivo.  
 
1.3.3 Pathological processes in the colon  
The term inflammatory bowel disease (IBD) is defined as a group of illnesses 
affecting the GI tract and manifested as inflammation of the bowel. Although 
inflammation is a primary process and usually confined to the digestive organs, the 
disease may affect almost any area of the body as an indirect consequence of the 
inflammation. It can be also associated with malnutrition and infection, or as a result 
of the side effects of drugs prescribed for treatment. The idiopathic IBD consists of 
ulcerative colitis and Crohn’s disease (Haeberlin and Friend, 1992). These diseases 
are primarily treated with various corticosteroids, mesalazine and 
immunosuppressants.  
 
Ulcerative colitis refers to an inflammation of the colon (large intestine or bowel) 
and does not spread to other areas of the intestines (Hanauer and Kirsber, 1985). 
Chronic ulcerative colitis affects the rectum or the sigmoid colon and progresses 
proximally to involve the entire left side of the colon. The first site of cell damage 
and death is the colonic crypts and the disease primarily involves the mucosal layer 
of the intestine resulting in chronic diarrhoea and abdominal pain. Crohn’s disease is 
granulomatous and can affect any part of the GI tract. In Crohn’s disease, the 
inflammation extends through all layers of the intestinal wall, which the mucosal 
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surface is reddened, nodular and cobblestone-like, with multiple linear ulcerations. 
The inflammatory infiltrate will thicken the mucosal layer, then the submucosa and 
serosa by fibrosis and finally the serosa by hypertrophy (Molema and Meijer, 2001).  
 
1.4 Strategies for targeting drugs to the colon 
The main purpose of the designation of colonic drug delivery systems is to take 
advantage of the conditions that are specific to the colon to gain release of drugs 
locally. However, targeting this region of the gut can be problematic as the colon 
represents the most distal segment of the GI tract. The most direct route for delivery 
of drugs into colon is by rectal administration via suppositories and enemas (Jay et 
al., 1985), but such formulations rarely succeed in spreading beyond the descending 
colon, with little or no drug reaching the proximal colon (Hardy et al., 1986). As 
most patients reject the rectal route, the oral route is preferable as mode of 
administration where it offers greater convenience, less pain, higher likelihood of 
compliance and reduced risk of cross-infection (Florence and Jani, 1993; Chen and 
Langer, 1998; Liu et al., 2003).  
 
The concept of oral route in colon-specific drug delivery is simple where the 
formulation must delay drug release in the stomach as well as small intestine but 
allow release in the colon.  As a result, the design of oral controlled release products 
is relying on gross characteristics of the GI tract, which is usually empirically based, 
rather than using cellular and molecular information. This is because a good 
formulation is needed to overcome the obstacles of conditions and environments on 
passage down the gut, including pH, enzymes, electrolytes, transit time and pressure 
(Basit, 2005). With the concept of drug targeting, which is based on the identification 
